Strides Pharma

Strides Pharma has reported a sharp 81% year-on-year increase in its consolidated net profit for the first quarter of FY25, reaching Rs. 114 crore. The robust growth was primarily attributed to improved performance in the U.S. generics market, better product mix, and strengthened operational efficiencies across global markets. Revenues for the quarter stood at Rs. 1,094 crore, marking a healthy rise, while EBITDA margin improved significantly due to cost optimization and strategic focus on high-margin formulations.

In a strategic push to strengthen its U.S. generics footprint, Strides Pharma Global Pte. Ltd., a wholly owned subsidiary of Strides Pharma Science Limited, has finalized an agreement to acquire a suite of Abbreviated New Drug Applications (ANDAs) from Kansas City-based Nostrum Laboratories. The portfolio includes four approved ANDAs and one pending FDA approval, with a focus on oral dosage forms targeting niche, high-margin therapeutic areas. This acquisition complements Strides’ broader strategy of bolstering its U.S. presence and scaling revenues in the regulated market.